MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Trial details
- Registry ID
- NCT03846219
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Vidofludimus Calcium, Oral Tablet (30 mg/day)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219 | Immunic AG | Phase 2 | Active not recruiting | 2020-04-24Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |